Even though no treatments are approved  at the moment for MERS-CoV infection, a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is being tested in humans in Saudi Arabia.

Interferons have been proved effective in vitro and in vivo against SARS-CoV and MERS-CoV, providing sinergy with lopinavir/ritonavir. Redemsivir has also proved to improve pulmonary function and reduce lung viral loads, both in prophylactic and therapeutic purposes, in mice.

The combination LPV/RTV-IFNb with a therapeutic purpose, however, does not reduce virus replication. Remdesivir and Interferon-beta show a higher antiviral activity to lopinavir and ritonavir.